NSRX · Nasus Pharma Ltd · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. |
Ordinary Shares
|
6,550 |
| 2026-04-22 | Teleman Dan Benjamin |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
Consists of: (i) 24,146 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. |
Ordinary Shares
|
2,900 |
| 2026-03-31 | Teleman Dan Benjamin |
Director, Chief Executive Officer |
Buy↑
|
Ordinary Shares
|
15,000 |